Department of Health and Human Services February 6, 2018 – Federal Register Recent Federal Regulation Documents
Results 1 - 9 of 9
Advisory Committee on Heritable Disorders in Newborns and Children
This notice announces a correction to the meeting announcement for a public meeting of the Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC), published in the Federal Register on January 22, 2018. The meeting has changed from a two-day meeting to a one-day meeting, to be held on Thursday, February 8, 2018. Agenda items have been updated and will include a final evidence-based review report on the spinal muscular atrophy (SMA) condition nomination for possible inclusion on the Recommended Uniform Screening Panel (RUSP). Following this report, the ACHDNC expects to vote on whether to recommend adding SMA to the RUSP to the Secretary of HHS. The agenda will also include presentation of a document on cutoff determinations and risk assessment methods used for dried bloodspot newborn screening. The Committee expects to vote on whether to support this document. The ACHDNC members will also consider a report on Quality Measures in Newborn Screening from the Follow up and Treatment Workgroup. HRSA will post the agenda two days prior to the meeting on the Committee's website: https:// www.hrsa.gov/advisory-committees/heritable-disorders/index.ht ml. Please note that agenda items are subject to changes as priorities dictate.
Agency Information Collection Activities: Proposed Collection; Comment Request
This notice announces the intention of the Agency for Healthcare Research and Quality (AHRQ) to request that the Office of Management and Budget (OMB) approve the proposed information collection project ``Expanding the Comprehensive Unit-based Safety Program (CUSP) to Reduce Central Line-Associated Blood Stream Infections (CLABSI) and Catheter-Associated Urinary Tract Infections (CAUTI) in Intensive Care Units (ICU) with Persistently Elevated Infection Rates.'' This proposed information collection was previously published in the Federal Register on July 28, 2017, and allowed 60 days for public comment. AHRQ did not receive any substantive public comments. In response to internal project team feedback, the proposed data collection has been modified in order to increase efficiency and decrease respondent burden. Modifications include consolidation of two data collection tools (the Team Checkup Tool and the ICU Assessment) into one ICU Assessment and decreasing the frequency of administration. The modifications also now require broad administration of the ICU Action Plan, which previously was administered only to those sites that had a site visit. The purpose of this notice is to allow an additional 30 days for public comment.
Advisory Committee on Immunization Practices (ACIP)
In accordance with the Federal Advisory Committee Act, the Centers for Disease Control and Prevention (CDC), announces the following meeting of the Advisory Committee on Immunization Practices (ACIP). This meeting is open to the public, limited only by room seating. Time will be available for public comment. The public is welcome to submit written comments in advance of the meeting. Comments should be submitted in writing by email to the contact person listed below. The deadline for receipt is February 14, 2018. Written comments must include full name, address, organizational affiliation, email address of the speaker, topic being addressed and specific comments. Written comments must not exceed one single-spaced typed page with 1- inch margins containing all items above. Only those written comments received 10 business days in advance of the meeting will be included in the official record of the meeting. Public comments made in attendance must be no longer than 3 minutes and the person giving comments must attend the public comment session at the start time listed on the agenda. Time for public comments may start before the time indicated on the agenda. The meeting will be webcast live via the World Wide Web; for instructions and more information on ACIP please visit the ACIP website: https://www.cdc.gov/vaccines/acip/.
This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.
